Apimeds Pharmaceuticals, has announced the next phase of its ai² Futures Lab initiative through a formal collaboration with the University of Oregon’s Lundquist College of Business, commencing in Winter 2026. The expansion positions the ai² Futures Lab as a growing nexus between academia and industry, designed to accelerate early-stage biopharma innovation while equipping emerging professionals with hands-on experience in translational business science.
As a proud University of Oregon alum, I couldn’t be more excited. The Lundquist College of Business is an ideal partner to help expand our ai² Futures Lab initiative. This program embodies what we value most at Apimeds—bridging human insight and scientific innovation. ai² Futures Lab fuels our pipeline with fresh, data-driven thinking, while allowing students at the University of Oregon to build on the Oregon tradition of innovation, collaboration and, as Oregon alumni appreciate, being your favorite team’s favorite team.
Erik Emerson, CEO of Apimeds Pharmaceuticals
The ai² Futures Lab operates as a dual-purpose platform: both a discovery engine for potential therapeutic assets and a development framework for future biopharma leaders. Within this new partnership, student teams from the University of Oregon will collaborate with Apimeds mentors to conduct market, intellectual property, and asset viability analyses. Their work will center on identifying untapped or shelved pharmaceutical candidates with potential to improve patient outcomes through novel commercialization pathways.
We’re thrilled to bring this hands-on opportunity to our students. Collaborating with an innovative partner like Apimeds provides real-world experience that helps prepare students for careers at the intersection of science, business, and innovation. It’s a perfect reflection of the Lundquist approach—learning by doing, with purpose and impact.
Bruce Blonigen, Edward Maletis Dean of the Lundquist College of Business
This initiative follows similar collaborations with the University of Alabama and the University of San Diego, reflecting Apimeds’ broader effort to integrate academic inquiry with industrial pragmatism. The ai² platform embodies the company’s philosophy of combining human analytical judgment with machine learning-driven insights to uncover transformative opportunities within the life sciences ecosystem.
This partnership deepens our mission to transform ai² Futures Lab into a scalable development platform for Apimeds and a launchpad for young innovators. Each team is working on real assets with real potential, creating value both for the company and for the students shaping the future of healthcare.
Brian Peters, SVP of Apimeds’ ai² Division and ai² Futures Lab program lead
From a scientific collaboration perspective, the program represents a hybrid model of experiential learning and data-driven discovery, bridging gaps between theoretical education, business innovation, and therapeutic advancement.